chevron_leftBack
As of 24 April 2025, BioNxt Solutions Inc. has a market cap of $38.33M USD, ranking #26609 globally and #829 in Canada. It ranks #2689 in the Healthcare sector, and #582 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$38.33MUSD
53.09M CAD
Enterprise Value
$42.24MUSD
58.62M CAD
Revenue (TTM)
$30.33KUSD
42.01K CAD
EBITDA (TTM)
-$3.8MUSD
-5.27M CAD
Net Income (TTM)
-$4.68MUSD
-6.48M CAD
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Wolfgang Probst
open_in_new
Founded
2017
Website
bionxt.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 5.8% | 5.7% | -21% | 7% | 88% | 28% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BNXT
BioNxt Solutions Inc Ordinary Shares
ISIN: CA0909741062
Shares Out.:
Shares Outstanding:
113.402M1
Shares Float:
106.552M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.4600 CAD | |
|
BNXT
BioNxt Solutions Inc Ordinary Shares
ISIN: CA0909741062
|
0.4500 CAD | |
|
BNXTF
BioNxt Solutions Inc Ordinary Shares
ISIN: CA0909741062
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.3250 USD | |
|
BXT
BioNxt Solutions Inc Ordinary Shares
ISIN: CA0909741062
Shares Out.:
Shares Outstanding:
113.402M1
Shares Float:
106.552M2
|
0.2750 EUR | |
|
BXT
BioNxt Solutions Inc Ordinary Shares
ISIN: CA0909741062
Shares Out.:
Shares Outstanding:
113.402M1
Shares Float:
106.552M2
|
0.2850 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
